Kınıkoğlu, O.; Öven, B.B.; Çelik, S.; Alan Selçuk, N.; Beydağı, G.; Akçay, K.; Kabasakal, L.
Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. J. Clin. Med. 2024, 13, 4585.
https://doi.org/10.3390/jcm13164585
AMA Style
Kınıkoğlu O, Öven BB, Çelik S, Alan Selçuk N, Beydağı G, Akçay K, Kabasakal L.
Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Medicine. 2024; 13(16):4585.
https://doi.org/10.3390/jcm13164585
Chicago/Turabian Style
Kınıkoğlu, Oğuzcan, Bala Başak Öven, Serkan Çelik, Nalan Alan Selçuk, Gamze Beydağı, Kaan Akçay, and Levent Kabasakal.
2024. "Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer" Journal of Clinical Medicine 13, no. 16: 4585.
https://doi.org/10.3390/jcm13164585
APA Style
Kınıkoğlu, O., Öven, B. B., Çelik, S., Alan Selçuk, N., Beydağı, G., Akçay, K., & Kabasakal, L.
(2024). Investigating Combination Therapy: The Role of Lutetium-177 PSMA-617 Radioligand Therapy and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Medicine, 13(16), 4585.
https://doi.org/10.3390/jcm13164585